MedTrace Logo

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

NCT06264752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 698

Last updated 2025-09-12

No results posted yet for this study

Summary

This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.

Conditions

Interventions

OTHER

Level A

Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.

OTHER

Level B

The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.

OTHER

Passive Alert

Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Sandra L Kane-Gill, PharmD, MS · University of Pittsburgh

  • Azra Bihorac, MD, MS · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-07-15
Completion
2025-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06264752 on ClinicalTrials.gov